Investigating specific FGFR signaling pathways in lung disease
Official title: Targeting Isoform-specific FGFR Signaling in Idiopathic Pulmonary Fibrosis
Funded at Yale University · NIH-11117642 · Data updated 2026-11-12
This study is looking at how certain proteins in the lungs might affect the worsening of Idiopathic Pulmonary Fibrosis (IPF) in older adults, with the hope of finding new treatments to help those living with this condition.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project start | May 15, 2025 |
| Project end | April 30, 2027 |
| Funding year | 2025 |
| Award (this year) | $461,146 |
| NIH project number | 1R21AG093265-01 |
| Project ID | NIH-11117642 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults over 65 years old who have been diagnosed with Idiopathic Pulmonary Fibrosis.
✕Less likely to help
Patients with other forms of lung disease or those under 21 years old may not benefit from this research.
What this research studies
This research focuses on Idiopathic Pulmonary Fibrosis (IPF), a serious lung condition primarily affecting older adults. The study aims to understand how different forms of the fibroblast growth factor receptor (FGFR) contribute to the disease's progression. By conducting laboratory studies on lung cells and using animal models, researchers will explore how targeting specific FGFR pathways may lead to new treatment options. This approach seeks to provide insights into the disease mechanisms and develop effective therapies for patients suffering from IPF.
Why it matters
Potential benefit: If successful, this research could lead to new, targeted treatments that effectively alleviate the symptoms and progression of Idiopathic Pulmonary Fibrosis.
How similar studies have gone: Previous research has shown promise in targeting specific signaling pathways in similar conditions, indicating potential for success in this approach.
Where this research is happening
-
Yale University
New Haven, United States Active
Researchers
- Principal investigator: Lee, Sangwon — Yale University
- Study coordinator: Lee, Sangwon
Related research
Other NIH-funded projects on the same topics.
-
Repurposing Pyrvinium as an Inhaled Therapy for Idiopathic Pulmonary Fibrosis
A patient-friendly look at a project trying to use an existing drug, pyrvinium, as an inhaled treatment option for idiopathic pulmonary fibrosis (IPF).
-
Screening new compounds to reverse gene signatures in IPF lungs
A researcher hopes to find compounds that reverse harmful gene changes in the lungs of people with idiopathic pulmonary fibrosis (IPF).
-
Unraveling IPF subtypes to guide prognosis and therapy
This grant aims to identify different IPF subtypes in the lung to improve how we predict outcomes and tailor treatments for people with IPF.
-
Novel antibody therapy to treat idiopathic pulmonary fibrosis
A small business gig is developing a targeted antibody drug (VSR-H5) to treat idiopathic pulmonary fibrosis in patients, aiming for better safety and effectiveness than current medicines.
-
Repurposing Vonoprazan as an inhaled therapy for IPF
A high-profile NIH grant is testing whether an existing drug, vonoprazan, can be inhaled to slow or reverse lung fibrosis in people with idiopathic pulmonary fibrosis (IPF).
-
Proteomic profile of IPF progression to help tailor treatments
A study will look for blood protein patterns that predict how IPF lung disease will progress in patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.